Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections

Journal of Infectious Diseases

Volumn 179, Issue SUPPL. 1, 1999, Pages

  Jahrling, Peter B ^a,b,c   Geisbert, T W ^a,b   Geisbert, J B ^a,b   Swearengen, J R ^a,b   Bray, M ^a,b   Jaax, N K ^a,b   Huggins, J W ^a,b   LeDuc, J W ^a,b   Peters, C J ^a,b  

^a U S ARMY   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; RECOMBINANT ALPHA2B INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; CONFERENCE PAPER; EBOLA VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FILOVIRIDAE; GUINEA PIG; INFECTION RISK; LASSA VIRUS; MACROPHAGE; MONKEY; MONOCYTE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; VIREMIA; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0033066490     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514310     Document Type: Conference Paper

References (37)

1. 1. McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986;314:20-6.
2. 2. Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991; 164: 1119-27.
3. 3. McKec KT Jr, Huggins JW, Trahan CJ, Mahlandt BG. Ribavirin prophylaxis and therapy for experimental Argentine hemorrhagic fever. Anti-microb Agents Chemother 1988;32:1304-9.
4. 4. Enria DA, Briggiler AM, Levis S, Vallejos E, Maiztegui JI, Canonico PG. Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever. Antiviral Res 1988;32:353-9.
5. 5. van de Wal BW, Joubert JR, van Eeden PJ, King JB. A nosocomial outbreak of Crimean-Congo hemorrhagic fever at Tygerberg Hospital. Part IV. Preventive and prophylactic measures. S Afr Med J 1985;68: 729-32.
6. 6. Fisher-Hoch SP, Khan JA, Rehman S, Mirza S, Khurshid M, McCormick JB. Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet 1995; 346:472-5.
7. 7. Barry M, Russi M, Armstrong L, et al. Brief report; treatment of a laboratory-acquired Sabia virus infection. N Engl J Med 1995;333:294-6.
8. 8. Peters CJ, Reynolds JA, Slone TW, Jones DE, Stephen EL. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an Interferon inducer, and a macrophage activator. Antiviral Res 1986; 6:285-97.
9. 9. Stephen EL, Jones DE, Peters CJ, Eddy GA, Loizeaux PS, Jahrling PB. Ribavirin treatment of toga-, arena-, and bunyavirus infections in subhuman primates and other animal species. In: Smith RA, Kirkpatrick W, eds. Ribavirin: a broad spectrum antiviral agent. New York: Academic Press, 1980:169-83.
10. 10. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989; 11(suppl):S750-61.
11. 11. Ignat'ev GM, Strel'tsova MA, Agafonov AP, Kashentseva EA, Prozorovskii NS. Experimental study of possible treatment of Marburg hemorrhagic fever with desferal, ribavirin, and homologous interferon. Vopr Virusol 1996;41:206-9.
12. 12. Monath TP. Ribavirin, interferon, and antibody approaches to prophylaxis and therapy for viral hemorrhagic fevers. Curr Opin Infect Dis 1990; 3:824-33.
13. 13. Bowen ETW, Lloyd G, Platt G, Meardell LB, Webb PA, Simpson DIH. Virological studies on a case of Ebola virus infection in man and monkeys. In: Pattyn SR, ed. Ebola virus hemorrhagic fever. Amsterdam; Elsevier/North-Holland Biomedical Press, 1978:95-100.
14. 14. Jahrling PB, Peters CJ. Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and virus strain, Infect Immun 1984;44:528-33.
15. 15. Maiztegui JI, Fernandez NJ, deDamilano AJ. Efficacy of immune plasma in treatment of Argentine hemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979;2:1216-7.
16. 16. Krasnyanskii VP, Mikhailov VV, Borisevich IV, Gradoboev VN, Evseev AA, Pshenichnov VA. Preparation of hyperimmune horse scrum to Ebola virus. Vopr Virusol 1994;39:91-2.
17. 17. Borisevich V, Mikhailov VV, Krasnyansky VP, et al. Creation and study of immunoglobulin to Ebola fever. Vopr Virusol 1995;40:270-3.
18. 18. Mikhailov VV, Borisevich IV, Chernikova NK, Potryvaeva Krasnyanskii VP. An evaluation of the possibility of Ebola fever specific prophylaxis in baboons (Papio hamadryas). Vopr Virusol 1994;39:82-4.
19. 19. Jahrling PB, Geisbert J, Swearengen JR, et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol 1996(suppl); 11:135-40.
20. 20. Englund JA, Piedra PA, Ahn YM, Gilbert BE, Hiatt P. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Pediatr 1994; 125:635-41.
21. 21. WHO Ebola haemorrhagic fever. Wkly Epidemiol Rec 1996;48:366.
22. 22. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178:651-61 and 1999; 179(suppl 1):S248-58.
23. 22. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178:651-61 and 1999; 179(suppl 1):S248-58.
24. 23. Connolly BM, Steele KE, Davis KJ, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999; 179(suppl 1): S203-17.
25. 24. Jahrling PB, Geisbert TW, Dalgard DW, et al. Preliminary report: isolation of Ebola virus from monkeys imported to the USA. Lancet 1990;335: 502-5.
26. 25. Jahrling PB. Filoviruses and arenaviruses. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. 6th ed. Washington, DC: ASM Press, 1995:1068-81.
27. 26. Ksiazek, TG. Laboratory diagnosis of filovirus infections in nonhuman primates. Lab Animal 1991;20:34-46.
28. 27. Geisbert TW, Jahrling PB, Hanes MA, Zack PM. Association of Ebola-related Reston virus particles and antigen with tissue lesions of monkeys imported to the United States. J Comp Pathol 1992; 106:137-52.
29. 28. Casadevall A, Scharff MD. Scrum therapy revisited: animal models of infection and development of passive antibody therapy, Antimicrob Agents Chemother 1994;38:1695-702.
30. 29. Davis KJ, Anderson AO, Geisbert TW, et al. Pathology of experimental Ebola virus infection in African green monkeys: involvement of fibroblastic reticular cells. Arch Pathol Lab Med 1997; 121:805-19.
31. 30. Feldmann H, Bugany H, Mahner F, Klenk H, Drenckhahn D, Schnittler H. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Virol 1996:2208-14.
32. 31. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 1999; 179(suppl 1):S18-23.
33. 32. Loginova SI, Bogatikov GV, Prikhod'ko AV, Polozov AI. Study of the effectiveness of recombinant α2-interferon and its inducers in primates with arthopoxvirus infection. Vopr Virusol 1997;42:186-99.
34. 33. Huggins J, Zhang ZX, Bray M. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J Infect Dis 1999; 179(suppl 1): S240-7.
35. 34. Jahrling PB, Peter CJ, Stephen EL. Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J Infect Dis 1984; 149:420-7.
36. 35. Jaax NK, Davis KJ, Geisbert TW, et al. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 1996; 120: 140-55.
37. 36. Jahrling PB, Geisbert TW, Jaax NK, Hanes MA, Ksiazek TG, Peter CJ. Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 US epizootic. Arch Virol 1996;(suppl 11):115-43.